Sanofi granted European approval for Dupixent in atopic dermatitis

Sanofi has been granted marketing authorisation for Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in certain adult patients.

The decision was widely anticipated, after the EMA’s advisory committee delivered a positive opinion on the therapy in July.

The drug was approved in this indication in the USA in March.

Dupilumab is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two proteins, IL-4 and IL-13.